AU2004208615B2 - Medicine for prevention of and treatment for arteriosclerosis and hypertension - Google Patents

Medicine for prevention of and treatment for arteriosclerosis and hypertension

Info

Publication number
AU2004208615B2
AU2004208615B2 AU2004208615A AU2004208615A AU2004208615B2 AU 2004208615 B2 AU2004208615 B2 AU 2004208615B2 AU 2004208615 A AU2004208615 A AU 2004208615A AU 2004208615 A AU2004208615 A AU 2004208615A AU 2004208615 B2 AU2004208615 B2 AU 2004208615B2
Authority
AU
Australia
Prior art keywords
arteriosclerosis
hypertension
medicine
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2004208615A
Other versions
AU2004208615C1 (en
AU2004208615A1 (en
Inventor
Masatsugu Horiuchi
Masaru Iwai
Makoto Mizuno
Toshio Sada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority claimed from PCT/JP2004/000861 external-priority patent/WO2004067003A1/en
Publication of AU2004208615A1 publication Critical patent/AU2004208615A1/en
Application granted granted Critical
Publication of AU2004208615B2 publication Critical patent/AU2004208615B2/en
Assigned to DAIICHI SANKYO COMPANY, LIMITED reassignment DAIICHI SANKYO COMPANY, LIMITED Request for Assignment Assignors: SANKYO COMPANY, LIMITED
Publication of AU2004208615C1 publication Critical patent/AU2004208615C1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

AU2004208615A 2003-01-31 2004-01-29 Medicine for prevention of and treatment for arteriosclerosis and hypertension Active 2025-05-14 AU2004208615C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2003-022990 2003-01-31
JP2003022990 2003-01-31
JP2003030830 2003-02-07
JP2003-030830 2003-02-07
PCT/JP2004/000861 WO2004067003A1 (en) 2003-01-31 2004-01-29 Medicine for prevention of and treatment for arteriosclerosis and hypertension

Publications (3)

Publication Number Publication Date
AU2004208615A1 AU2004208615A1 (en) 2004-08-12
AU2004208615B2 true AU2004208615B2 (en) 2007-05-03
AU2004208615C1 AU2004208615C1 (en) 2010-05-13

Family

ID=32828917

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004208615A Active 2025-05-14 AU2004208615C1 (en) 2003-01-31 2004-01-29 Medicine for prevention of and treatment for arteriosclerosis and hypertension

Country Status (20)

Country Link
US (6) US20060009502A1 (en)
EP (2) EP1604664A4 (en)
JP (2) JP3874419B2 (en)
KR (2) KR20120058618A (en)
AU (1) AU2004208615C1 (en)
BR (1) BRPI0406987A (en)
CA (1) CA2514921C (en)
CR (1) CR7928A (en)
EA (1) EA009983B1 (en)
EC (1) ECSP055935A (en)
HR (1) HRP20050754A2 (en)
IL (1) IL169719A (en)
IS (1) IS7985A (en)
ME (1) ME00479B (en)
MX (1) MXPA05008142A (en)
NZ (1) NZ541454A (en)
PL (1) PL377344A1 (en)
RS (1) RS20050590A (en)
TW (1) TWI373335B (en)
WO (1) WO2004067003A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006131511A (en) * 2004-11-02 2006-05-25 Japan Health Science Foundation Ischemic encephalopathy inhibitor
MX2007012635A (en) * 2005-04-12 2008-01-11 Vicore Pharma Ab New tricyclic angiotensin ii agonists.
US8080571B2 (en) * 2005-04-12 2011-12-20 Vicore Pharma Ab Tricyclic angiotensin II agonists
TWI367755B (en) * 2005-05-20 2012-07-11 Sankyo Co Film coated product
TWI367756B (en) * 2005-05-20 2012-07-11 Sankyo Co A film-coated drug product comprising dextrose
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
KR101422052B1 (en) * 2006-04-19 2014-07-23 아지노모토 가부시키가이샤 Scored tablet
SI1891952T1 (en) * 2006-05-04 2012-02-29 Lek Pharmaceuticals, D.D. Pharmaceutical composition of olmesartan medoxomil
BRPI0713371A2 (en) * 2006-06-27 2012-03-13 Daiichi Sankyo Company, Limited method for producing a medicament containing olmesartan medoxomil, and medicament containing olmesartan medoxomil
TWI399223B (en) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd Solid dosage form of olmesartan medoxomil and amlodipine
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
TWI402083B (en) * 2006-12-26 2013-07-21 Daiichi Sankyo Co Ltd Solid dosage form and stabilization method thereof
TWI488658B (en) * 2006-12-26 2015-06-21 Daiichi Sankyo Co Ltd Method for improvement of elution
TWI414310B (en) * 2006-12-26 2013-11-11 Daiichi Sankyo Co Ltd Elution-improved pharmaceutical preparation
JP2008290989A (en) * 2007-05-28 2008-12-04 Ube Ind Ltd Pharmaceutical comprising acid addition salt of dihydropyridine derivative
US8133924B2 (en) * 2007-08-13 2012-03-13 Rhodia Operations Demulsifiers and methods for use in pharmaceutical applications
WO2009113420A1 (en) 2008-03-13 2009-09-17 第一三共株式会社 Improvement of dissolvability of preparation containing olmesartan medoxomil
US20110256221A1 (en) * 2008-12-30 2011-10-20 Farhad Farshi Pharmaceutical formulations of olmesartan
JP6081058B2 (en) * 2009-03-19 2017-02-15 第一三共株式会社 Solid formulation stably stored by packaging
IT1400311B1 (en) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa ASSOCIATION OF INHIBITORS OF XANTHIN OXIDASE AND ANTAGONISTS OF THE Angiotensin II RECEPTOR AND THEIR USE.
CN113840538A (en) 2019-05-21 2021-12-24 雀巢产品有限公司 Dietary butyrate

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (en) 1982-03-11 1991-12-09 Pfizer CHANGES FOR THE PREPARATION FOR THE PREPARATION OF 2-Amino-CO-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-2-D-Hydroxy
US4573909A (en) * 1984-08-03 1986-03-04 Granco-Clark, Inc. Billet heating furnace with adjustable pressurized entrance seal
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4772596A (en) 1986-10-09 1988-09-20 Sankyo Company Limited Dihydropyridine derivatives, their preparation and their use
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2681067B1 (en) 1991-09-10 1993-12-17 Elf Sanofi N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5260285A (en) * 1990-12-07 1993-11-09 Merck & Co., Inc. Substituted imidazopyridazines as angiotensin II antagonists
US5250521A (en) * 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
CA2098176C (en) 1990-12-14 2006-12-12 Joseph Weinstock Angiotensin ii receptor blocking compositions
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
US5238942A (en) * 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
US5246944A (en) 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
FR2688781B1 (en) 1992-03-23 1994-07-01 Sanofi Elf IMIDAZOLINES N-SUBSTITUTED BY A BIPHENYLMETHYL GROUP, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JP2750331B2 (en) * 1992-04-23 1998-05-13 株式会社ジャパンエナジー Substrate for epitaxial growth and epitaxial growth method
US5312820A (en) * 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5343167A (en) * 1993-02-03 1994-08-30 Silicon Systems, Inc. One-shot control circuit for tracking a voltage-controlled oscillator
JP3057471B2 (en) * 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
GB9405833D0 (en) * 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US5808084A (en) * 1996-02-14 1998-09-15 Pfizer, Inc. Process for the preparation of 1,4-dihydropyridinedicarboxylic esters
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
RO118870B1 (en) 1996-03-29 2003-12-30 Smithkline Beecham Corporation (e)-alpha-[2-n-buthyl-1-[(4-carboxyphenyl)methyl]-1h-imidazole-5-yl]methylene -2-thiophenepropionic acid monomethanesulphonate, processes for its production and pharmaceutical compositions.
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
DE69734405T2 (en) * 1996-07-15 2006-08-03 Sankyo Co., Ltd. Use of CS-866 (Olmersartan) for the manufacture of a medicament for the treatment of arteriosclerosis
US5879303A (en) * 1996-09-27 1999-03-09 Atl Ultrasound Ultrasonic diagnostic imaging of response frequency differing from transmit frequency
JP4475685B2 (en) 1997-06-27 2010-06-09 スミスクライン・ビーチャム・コーポレイション Eprosartan monohydrate
TR200000350T2 (en) 1997-08-06 2000-12-21 Smithkline Beecham Corporation Eprosartan arginyl loading-neutralization-complex and its production process and formulation.
US6630498B2 (en) * 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
NZ504565A (en) 1997-11-17 2002-11-26 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations of eprosartan used to block angiotensin II (AII) receptors in the treatment of hypertension, congestive heart failure and renal failure
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ZA991922B (en) 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
US20030022928A1 (en) * 1998-03-11 2003-01-30 Smithkline Beecham Corporation Novel compositions of eprosartan
HUP0103206A3 (en) 1998-06-25 2002-11-28 Lavipharm Lab Inc Piscataway A device and method for the treatment of erectile dysfunction and for its making
US20020127254A1 (en) * 1998-06-25 2002-09-12 Lavipharm Laboratories Inc. Devices for local and systemic delivery of active substance and methods of manufacturing thereof
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
WO2000027396A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
EP1153037A1 (en) * 1999-02-09 2001-11-14 Lexicon Genetics Incorporated Human uncoupling proteins and polynucleotides encoding the same
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP2001089393A (en) * 1999-07-21 2001-04-03 Takeda Chem Ind Ltd Prophylactic agent for relapse of cerebrovascular disorder and ameliorator and evolution inhibitor for sequelae of cerebrovasular disorder
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
GB0008332D0 (en) 2000-04-04 2000-05-24 Pfizer Ltd Treament
ES2263604T5 (en) 2000-04-10 2017-02-07 Nicholas John Wald Formulation for the Prevention of Cardiovascular Disease
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
JP4327376B2 (en) * 2000-04-11 2009-09-09 第一三共株式会社 Stabilized pharmaceutical composition containing calcium blocker
WO2001076598A1 (en) * 2000-04-11 2001-10-18 Sankyo Company, Limited Stabilized pharmaceutical compositions containing calcium channel blockers
DE10018401A1 (en) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Medicament for treating hypertrophy-related myocardial disease, containing bradycardic agent, preferably cilobradine, and optionally another cardiac drug
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
DK1336407T3 (en) * 2000-11-21 2006-09-04 Sankyo Co Composition containing an angiotensin II receptor antagonist and a diuretic and its use in the treatment of hypertension
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical Sustained-release medicines
BR0212254A (en) * 2001-08-28 2004-10-19 Sankyo Co Pharmaceutical Composition
US6680334B2 (en) * 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
WO2003035039A1 (en) * 2001-10-25 2003-05-01 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP5100039B2 (en) * 2003-01-31 2012-12-19 第一三共株式会社 Pharmaceuticals for the prevention and treatment of arteriosclerosis and hypertension
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050209588A1 (en) * 2003-09-04 2005-09-22 Crum, Kaminski & Larson, Llc HIFU resculpturing and remodeling of heart valves
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker

Similar Documents

Publication Publication Date Title
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
EP1604664A4 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003219934A1 (en) Method of treatment or prevention of obesity
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
AU2003900747A0 (en) Diagnosis and treatment of pancreatic cancer
AU2003232485A1 (en) Neopeptides and methods useful for detection and treatment of cancer
IL180517A0 (en) Novel statin pharmaceutical compositions and related methods of treatment
AU2003234257A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
AU2003229923A1 (en) Curcumin for the prevention and/or treatment of tissue damage
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2002323823A1 (en) Medicament for prevention and treatment of fracture and osteoporosis
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
AU2003217971A1 (en) Gas-plasma treatment of implants
AU2003273762A1 (en) Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2003231279A1 (en) Prevention and treatment of type 2 diabetes
AU2003264954A1 (en) Pharmaceutical composition for prevention and treatment of kidney diseases
ZA200701916B (en) Novel statin pharmaceutical compositions and related methods of treatment
AU2003227257A1 (en) Medicine for prevention and/or therapy of cardiomyopathy
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore
AU2003274359A1 (en) Treatment of fluids